LOX and glioblastoma: These in vivo results coupled with the recent findings observed in patients with GBM showing that PTEN mutations and macrophage abundance are enriched in anti-PD1 therapy nonresponders compared to responders (28), reinforces the importance of macrophages in regulating anti-PD1 therapy resistance and supports the treatment strategy of combining LOX inhibitors and anti-PD1 therapy specifically in PTEN-deficient GBM.